FDA Approves New Combination Therapy for Muscle-Invasive Bladder Cancer

Muscle-invasive bladder cancer limits treatment choices for patients unable to receive cisplatin, but a regulatory decision on Friday by the Food and Drug Administration introduces a combination therapy of durvalumab and enfortumab vedotin that clinical trials show improves survival.

When the disease breaches the muscular wall of the bladder, clinicians frequently perform a radical cystectomy. Preoperative and postoperative drug regimens aim to improve surgical success, but standard cisplatin-based chemotherapy remains contraindicated for patients with renal impairment or other vulnerabilities. The new FDA approval addresses this population by pairing an immunotherapy agent with an antibody-drug conjugate.

  • Mechanism of Action: Durvalumab activates the patient’s immune system to target tumor cells, while enfortumab vedotin uses a molecular carrier to deliver a cytotoxic payload directly to cancer cells expressing the nectin-4 protein.
  • Treatment Protocol: Patients undergo three cycles of the combined regimen before surgery, followed by up to nine cycles of maintenance therapy with durvalumab alone after the bladder is removed.

The international VOLGA trial, published in the New England Journal of Medicine, evaluated 695 patients across multiple study arms to measure the efficacy of the protocol. Researchers compared 233 patients receiving the durvalumab and enfortumab vedotin combination against 229 patients assigned to a surgical control group.

FDA Approves New Combination Therapy for Muscle-Invasive Bladder Cancer #Shorts — Nowly News

At the two-year mark, estimated overall survival reached 78.4% in the combination therapy cohort, compared with 69.4% in the control group. This represents an absolute difference of nine percentage points. Event-free survival showed a similar divergence, registering at 63.5% versus 45.1%.

Endpoint (2-Year Estimate) Combination Therapy (Durvalumab + Enfortumab Vedotin) Surgical Control Group
Overall Survival 78.4% 69.4%
Event-Free Survival 63.5% 45.1%
Grade 3+ Adverse Events (Total) 71.1% 50.2%

Statistical evaluations from the trial also demonstrated a relative reduction of 42% in the risk of death and a 49% reduction in the risk of secondary clinical events. These figures reflect statistical probabilities over the observed period rather than universal guarantees of efficacy.

Durvalumab + Enfortumab vedotin FDA Approval for Muscle Invasive Bladder Cancer (MIBC): VOLGA — OncBrothers: Practice-Changing Cancer Discussions

Severe adverse events of grade 3 or higher appeared in 71.1% of patients receiving the combination therapy, compared to 50.2% in the control group. When isolating events directly caused by the drugs, 30.7% of the experimental group had serious complications, including peripheral neuropathies, cutaneous reactions, and immune-mediated toxicities.

Therapeutic decisions require individualized assessments of general health status, renal and hepatic organ function, and the balance between potential survival benefits and treatment risks. Patients experiencing new neurological deficits, severe skin rashes, or metabolic irregularities during treatment must consult their oncology care team immediately for clinical triage.

The FDA review utilized Project Orbis, an international collaborative framework that enables simultaneous oncology drug evaluations across multiple global regulatory bodies. This mechanism aims to streamline reviews while preserving independent scientific determinations for each participating agency.

American regulatory clearance does not grant automatic availability or reimbursement through Italy’s National Health Service, the Servizio sanitario nazionale. Adoption into routine clinical practice across Italy requires subsequent European Medicines Agency authorizations and formal reimbursement determinations from the Agenzia Italiana del Farmaco.

In the interim, uro-oncology networks must establish multidisciplinary tumor boards comprising urologists, medical oncologists, and radiologists. Proper patient selection and toxicity management remain essential to ensure that innovations reach appropriate candidates efficiently.

  • Food and Drug Administration (FDA). Published November 13, 2026.
  • Powles T. et al. New England Journal of Medicine, published October 24, 2026.
  • ClinicalTrials.gov.
Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

Cumberland DA Office Olympics Build Resiliency to Combat Trauma